Immunovant Inc [IMVT] stock prices are up 2.76% to $16.74 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IMVT shares have gain 8.42% over the last week, with a monthly amount glided 19.40%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immunovant Inc [NASDAQ: IMVT] stock has seen the most recent analyst activity on March 03, 2025, when Jefferies initiated its Hold rating and assigned the stock a price target of $20. Previously, Wolfe Research downgraded its rating to Peer Perform on January 03, 2025. Oppenheimer reiterated its Outperform rating and increased its price target to $53 on October 09, 2024. Oppenheimer initiated its recommendation with a Outperform and recommended $50 as its price target on March 28, 2024. Goldman started tracking with a Buy rating for this stock on March 13, 2024, and assigned it a price target of $50. In a note dated February 20, 2024, JP Morgan initiated an Overweight rating and provided a target price of $51 on this stock.
The stock price of Immunovant Inc [IMVT] has been fluctuating between $12.72 and $34.47 over the past year. Currently, Wall Street analysts expect the stock to reach $42.83 within the next 12 months. Immunovant Inc [NASDAQ: IMVT] shares were valued at $16.74 at the most recent close of the market. An investor can expect a potential return of 155.85% based on the average IMVT price forecast.
Analyzing the IMVT fundamentals
An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Immunovant Inc [NASDAQ:IMVT]’s Current Ratio is 11.16. As well, the Quick Ratio is 11.16, while the Cash Ratio is 10.38.
Transactions by insiders
Recent insider trading involved WILLIAM MACIAS, Officer, that happened on Jun 03 ’25 when 80000.0 shares were purchased. Former Director, GEORGE V MIGAUSKY completed a deal on May 21 ’25 to buy 21812.0 shares. Meanwhile, Former Director GEORGE V MIGAUSKY bought 28188.0 shares on May 19 ’25.
